Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.
- Conditions
- Glaucoma
- Interventions
- Drug: Monopex 1 mg/ml, Théa
- Registration Number
- NCT04054830
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
PURPOSE:
Glaucoma is the leading cause of non-curable blindness globally. Patients with glaucoma will get a gradual narrowing of the visual fields caused by compression at the optic nerve head due to increased intraocular pressure. Thus the main preventive strategy is to reduce intraocular pressure, initially by eye drops and/or laser treatment but in some patients surgery is warranted. The surgical procedure (trabeculectomy) most widely performed worldwide creates a path from the anterior chamber to the subconjunctival space and thereby lowers the IOP by producing a more efficient drainage of the aqueous humour. Surgical success depends upon controlling post-operative inflammation to ensure a functional drainage. The purpose of this blinded, randomized study is to investigate which anti-inflammatory treatment provides better long-term control of intra-ocular pressure (IOP) following glaucoma surgery (trabeculectomy) by comparing topical NSAIDs to topical steroids. Additionally, we want to explore the mechanisms behind the pathophysiology of glaucoma by evaluating retinal and optic nerve head perfusion before and after IOP lowering surgery. The primary outcome is the intraocular pressure 12 months after surgery measured by applanation tonometry.
MAIN HYPOTHESIS:
* NSAIDs and steroids are equally effective in assuring long-term filtering function and controlling IOP after trabeculectomy but may be associated with different risk profiles and bleb morphology
* Patients with lower post-operative IOP demonstrate less progression of visual field loss
* Trabeculectomy lowers IOP and provides better microcirculation in and oxygenation of inner retinal layers (i.e. ganglion cell layer) and the optic nerve head
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 70
- Patients with primary open-angle glaucoma (POAG), pseudoexfoliation syndrome (PEX), pigment dispersion syndrome (PDS) or ocular hypertension
- >50 years
- Women must be postmenopausal. Women are asked if they have menstruated within the preceding 12 months
- Scheduled to undergo trabeculectomy surgery at the Department of Ophthalmology at Rigshospitalet-Glostrup, Denmark
- Informed consent to participation and ability to comply with study procedures
- Known allergy to any of the contents of the pharmaceuticals (active and in-active ingredients) used in the study
- Prior intraocular surgery, except from cataract surgery. If cataract surgery has been performed, it should at least be 6 months prior to surgery
- Medical history of anterior segment dysgenesis, inflammatory/uveitic glaucoma, angle closure glaucoma, neovascular glaucoma and traumatic glaucoma
- Steroid responders
- Pregnancy
- Fertile women, i.e. women who are not menopausal and women who breastfeed
- Patients in systemic treatment with steroid or NSAID
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Topical, preservative-free NSAID Voltaren Ophtha 1 mg/ml, GSK Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week. Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK Voltaren Ophtha 1 mg/ml, GSK Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK Monopex 1 mg/ml, Théa Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee Topical, preservative-free steroid Monopex 1 mg/ml, Théa Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
- Primary Outcome Measures
Name Time Method Intraocular pressure (IOP) 12 months Postoperative intraocular pressure (IOP) by applanation tonometry
- Secondary Outcome Measures
Name Time Method Visual field 12 months, 24 months Postoperative changes in visual field by octopus autoperimetry. (MD)
Optical nerve damage 12 months, 24 months Optical nerve damage, assessed by measuring retinal nerve fiber layer (RNFL) by peripapillary optical coherence tomography (OCT)
Best corrected visual acuity 12 months, 24 months Postoperative best corrected visual acuity in logarithm to the minimal angle of resolution (logMAR)
Surgical success 12 months, 24 months The definition of surgical success criteria is dependent on the the severity of visual field defect (MD, mean deviation of visual sensitivity compared to those expected from the age-matched normative database) glaucoma diagnosis and achievement of target pressure without the use of medication (complete success) or with the use of glaucoma medication (qualified success)
* Ocular hypertension, target \<25 mmHg
* MD \< 6 dB, target \< 21 mmHg
* MD 6 dB - 12 dB, target \<18 mmHg
* MD \> 12 dB, target \< 15 mmHg
Trial Locations
- Locations (1)
Department of Ophthalmology
🇩🇰Glostrup, Capital Region,, Denmark